Halden

The dressing that knows a wound is infected before the patient does.

A smart post-surgical dressing that spots infection up to 48 hours before a fever, and alerts the surgical team.

Seed round · Raising $1.5M

THE PROBLEM

Surgical infections are found too late, after the patient has gone home.

1 in 30

surgical patients develops a surgical site infection.

$20K+

added cost of each infection, from readmission and treatment.

Most

infections appear after discharge, when nobody is looking at the wound.

Today, patients are told to watch for redness and fever. By the time they call, the infection is established and they are back in the hospital.

THE SOLUTION

The Halden Dressing

- A standard adhesive dressing with a thin, flexible sensor strip
- Measures wound pH and temperature every 15 minutes
- Pairs with the patient’s phone over Bluetooth
- Our algorithm detects the early signature of infection
- Alerts the surgeon’s team through a simple web dashboard

How it works for a patient

1. Dressing applied in the OR
2. Patient goes home, phone pairs automatically
3. Dressing changed every 3 days, 5 dressings per surgery
4. Care team alerted only if something changes

TRACTION

Early validation is strong.

Working prototype

Our bench prototype detected the pH shift in a lab wound model with 94% accuracy.

Surgeons want it

We interviewed 12 surgeons. 9 said they would use Halden on their patients.

Hospital interest

A letter of interest from a regional hospital system to run our first pilot.

First patient pilot planned for next spring.

MARKET

A $4 billion market, and we only need 1%.

$4B

US advanced wound care dressings market.

10M+

inpatient surgeries in the US every year.

$40M

revenue at just 1% of the market.

There is no smart dressing for infection on the market today. Halden will be first.

BUSINESS MODEL

Hospitals save money on every patient.

What we charge

$45 per dressing, 5 dressings per surgery: **$225 per patient**.

Sold directly to hospitals.

What the hospital saves

One avoided infection pays for **89 patients** on Halden.

Remote patient monitoring billing codes can cover the cost.

Gross margin above 70% at scale.

REGULATORY

A fast, low-risk path to market.

- Wound dressings are Class I devices and exempt from FDA premarket review
- No clinical trial required before launch
- Launch in 12 months, starting with our pilot hospital

TEAM AND THE ASK

Raising $1.5M to launch.

Team

Founder and CEO: biomedical engineering PhD candidate, wound sensing research.

Co-founder: surgical nurse, 8 years in post-op care.

Use of funds (18 months)

Finish the product · Patient pilot · FDA clearance · First 10 hospital customers

hello@haldenhealth.example